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Objectives
The aim of the study was to statistically model the relative increased risk of cardiovascular
disease (CVD) per year older in Data collection on Adverse events of anti-HIV Drugs (D:A:D) and
to compare this with the relative increased risk of CVD per year older in general population risk
equations.
Methods
We analysed three endpoints: myocardial infarction (MI), coronary heart disease (CHD: MI or
invasive coronary procedure) and CVD (CHD or stroke). We fitted a number of parametric age
effects, adjusting for known risk factors and antiretroviral therapy (ART) use. The best-fitting
age effect was determined using the Akaike information criterion. We compared the ageing
effect from D:A:D with that from the general population risk equations: the Framingham Heart
Study, CUORE and ASSIGN risk scores.
Results
A total of 24 323 men were included in analyses. Crude MI, CHD and CVD event rates per 1000
person-years increased from 2.29, 3.11 and 3.65 in those aged 40–45 years to 6.53, 11.91 and
15.89 in those aged 60–65 years, respectively. The best-fitting models included inverse age for
MI and age + age2 for CHD and CVD. In D:A:D there was a slowly accelerating increased risk of
CHD and CVD per year older, which appeared to be only modest yet was consistently raised
compared with the risk in the general population. The relative risk of MI with age was not
different between D:A:D and the general population.
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Conclusions
We found only limited evidence of accelerating increased risk of CVD with age in D:A:D
compared with the general population. The absolute risk of CVD associated with HIV infection
remains uncertain.
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Introduction
Successfully treated HIV-positive people remain at
increased risk of a number of age-related non-AIDS mor-
bidities, such as cardiovascular disease (CVD), cancer, and
liver and kidney diseases [1]. A number of studies suggest
that these complications occur at a higher rate among
HIV-positive patients compared with general populations
[2,3]. HIV-positive persons have also been reported to
experience greater multimorbidity than general popula-
tions [4]. Careful interpretation of these studies is required
as the comparisons are often with unmatched HIV-negative
populations, or population based, or retrospective in
nature, probably resulting in unmeasured confounding.
CVD events in HIV-positive patients have been reported
to occur at higher rates compared with HIV-negative or
general populations of similar age [4–7]. Triant et al. dem-
onstrated not only a consistently higher rate of myocardial
infarction (MI) for all age groups in HIV-positive compared
with HIV-negative persons, but that the difference in
rates between HIV-positive and HIV-negative persons
also increased with age [5]. Currier et al. demonstrated
increased rates of CVD in HIV-positive compared with
HIV-negative persons in the younger age groups of 18–34
years in men and up to 44 years in women. Yet, by age ≥65
years, rates were higher in HIV-negative people, probably
as a result of HIV-positive individuals dying earlier [8].
Rates of MI, for instance, have been reported in various
studies to range from 1.11 to 3.5 per 1000 person-years
among HIV-positive patients [5,7,9,10]. However, the risk
of CVD in HIV-positive people is influenced not only by
the traditional cardiovascular risk factors, which are highly
prevalent in this now ageing population, genetics and
family history, but also by the effect of antiretroviral
therapy (ART), and the effect of HIV itself. It is well known
that the risk of CVD increases with age, yet it remains
unclear whether this age-related increase is more rapid
in HIV-positive people than in the general HIV-negative
population. Results to date have primarily relied on com-
parisons with general populations. Some comparisons
matched for age and sex, but not many for the remaining
risks factors, in particular smoking.
We hypothesized that, if the risk of CVD increases faster
with age in HIV-positive people, then we would expect the
relative increased risk of CVD events per year older to be
higher in Data collection on Adverse events of anti-HIV
drugs (D:A:D) than in the general population. The objective
of this study therefore was to statistically model in detail the
relative increased risk of CVD per year older in D:A:D and to
compare this with the relative increased risk of CVD per year
older in the general population risk equations.
Methods
The D:A:D cohort has been described in detail previously [9].
In brief, the D:A:D study is a prospective, multi-cohort
observational collaborative study, including 11 previously
established cohorts of 49 734 HIV-positive patients followed
at 212 clinics in Europe, Argentina, Australia and the USA.
The primary objective of the study was to investigate the
possible association between combination antiretroviral
therapy (cART) and the risk of MI. Patients were under active
follow-up in the individual cohorts, and were included in
D:A:D irrespective of whether or for how long they had been
receiving ART. Data were collected as part of routine clinical
care and included demographic and other prospectively
collected data, such as age, sex, body mass index (BMI),
hepatitis B and C status, history of CVD, diabetes mellitus
(DM), family history of CVD, cigarette smoking, DM therapy,
lipid-lowering and antihypertensive therapy, and serum
lipid levels. HIV-related core clinical data collected include
mode of HIV transmission, ART received, CD4 count, viral
load and all clinical AIDS diagnoses.
Inclusion criteria
In this analysis we included men without prior CVD and with
conventional CVD risk factors available [covariates identi-
fied in the D:A:D CVD risk equation: age, gender, family
history of CVD, smoking, cumulative (per year) lopinavir
and indinavir use, recent (within 6 months) abacavir use,
diabetes, cholesterol, high-density lipoprotein (HDL) choles-
terol and systolic blood pressure]. Similar inclusion criteria
were used to develop the D:A:D CVD risk equation [11].
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Analyses were limited to men because the vast majority of
CVD endpoints in D:A:D are in men (> 90%), meaning that
we were able to estimate the ageing effect in men most
accurately. We would have limited power to accurately
estimate a different ageing effect in women.
We analysed three endpoints: MI, coronary heart disease
(CHD: MI or invasive coronary procedure or CVD death)
and CVD (CHD or stroke). These events also included death
from these causes. Baseline was the time at which all risk
factors were first present. Follow-up ended at a CVD event,
the date of loss to follow-up (defined as the date on which
the patient last attended for care plus 6 months for patients
whose last clinic visit was at least 1 year prior to data
close-out) or 1 February 2011, whichever occurred first.
Statistical methods
Determination of the best-fitting age effect
We refitted a number of parametric age effects to the risk
of CVD, adjusting for the known risk factors and ART use
in the D:A:D CVD prediction equation [8]. The age effects
considered were: linear age (as originally fitted in the
D:A:D CVD risk equation), age2, age3, age0.5, age + age2 ,
inverse age, square-root of age, natural logarithm of age
(log age), (log age)2, (log age)3, (log age)0.5, and log age +
(log age)2. Poisson regression analyses were used to fit
each of the age effects, and the best-fitting age effect was
determined using the Akaike information criterion (AIC).
The AIC is a measure of the quality of the model selection;
the lower the AIC the better the model fit.
Sensitivity analyses
We conducted several sensitivity analyses to assess the
consistency of the best-fitting age effect for each of the
three endpoints: (1) adjusting for calendar year; (2) adjust-
ing for participating cohort; (3) adjusting for time since
entry into D:A:D; (4) restricting the analysis to age < 65
years, and (5) including men with missing risk factors.
Comparison with general risk equations
We compared the best-fitting D:A:D age effects with general
population CVD risk equations that included broadly similar
endpoints, gave age parametric forms for men, followed
patients prospectively, and had active ascertainment for
these endpoints. These were the Framingham Heart Study
risk scores by Anderson et al. (FHS_A) [12], Wilson et al.
(FHS_W) [13] and D’Agostino et al. (FHS_D) [14], including
more than 5500 men aged between 30 and 74 years; the
CUORE risk score [15], derived from a study including a
combination of 11 Italian cohorts with more than 6800 men
aged between 35 and 69 years; and the ASSIGN risk score
[16], derived from the Scottish Heart Health Extended cohort
study, which includes several cohorts with more than 6000
men aged between 30 and 74 years. Other general equations
initially considered but subsequently excluded were the
Prospective Cardiovascular Munster study (PROCAM) [17]
and QRISK (derived from the QResearch database) [18]. The
decision to exclude these equations was predominately
because of their follow-up procedures. In PROCAM [17],
follow-up was passive, occurring every 2 years via ques-
tionnaire. If there was evidence of mortality or morbidity
then hospital and attending physician records were
obtained. In QRISK1 [18], follow-up was through record
linkage to hospital admissions and death records.
Relative risk
As the absolute risk of CVD is known to differ between
populations [19], and the absolute effect of HIV infection
on CVD risk is uncertain, we compared the relative
increased risk of CVD per year older in the D:A:D data with
general risk equations. The D:A:D and general population
models were compared by graphing relative risk increase
from age 40 years to age 65 years. The general population
risk equations used parametric (FHS_A) or Cox regression
models (FHS_W, FHS_D, CUORE and ASSIGN) to determine
the relative hazards for age. Each of the equations fitted
different age effects [log age (FHS_A and FHS_D) or linear
(FHS_W, CUORE and ASSIGN)]. As we did not have access
to the raw data from these general population risk equa-
tions, formal statistical comparisons were not possible.
However, 95% confidence intervals (CIs) for the D:A:D
models were included to illustrate variability. It was not
possible to obtain CIs for the general population models
because the standard errors for the respective age coeffi-
cients were not reported for these equations.
Risk modification
Finally, to assess how the increasing risk of CVD with
ageing in D:A:D might be reduced with changes in other
modifiable risk factors, we also plotted the relative risk
increases with age, by investigating individually the impact
of stopping smoking, reducing cholesterol by 1 mmol/mL,
or reducing systolic blood pressure by 10 mmHg, at the
age of 50 years. All the remaining CVD risk factors were
assumed to be equal for all ages up to age 50 years, at which
time risk was modified. This approach assumes an instan-
taneous change in risk, although, in reality, the change in
risk would be more gradual.
Results
A total of 24 323 men were included in the analyses.
Table 1 presents baseline characteristics for this population.
Increased risk of CVD with age in HIV-positive men 597
© 2014 British HIV Association HIV Medicine (2014), 15, 595–603
Median age at enrolment was 41 [interquartile range (IQR)
35–48] years, and main modes of HIV acquisition were:
homosexual sex (60%), heterosexual sex (20%), and inject-
ing drug use (15%). Among some of the general CVD risk
factors, median baseline HDL cholesterol was 1.09 (IQR
0.88−1.32) mmol/L, median baseline total cholesterol
was 4.90 (IQR 4.06−5.80) mmol/L, and 55% were current
smokers and 18% ex-smokers. The median cART exposure
was 1.94 (IQR 0−3.87) years.
Total follow-up was 139 115 person-years, including 474
MI, 683 CHD and 884 CVD incident events. Crude MI, CHD
and CVD event rates per 1000 person-years increased from
2.29 (95% CI 1.80–2.88), 3.11 (95% CI 2.53–3.79) and 3.65
(95% CI 3.02–4.38) in those aged 40–45 years to 6.53 (95%
CI 4.73–8.78), 11.91 (95% CI 9.41–14.86) and 15.89 (95% CI
12.95–19.26) in those aged 60–65 years, respectively.
Determining best-fitting D:A:D age effects
Table S1 reports the various age effects as fitted to the
D:A:D data for each of the endpoints. The top five best-
fitting age effects were similar for all endpoints. These
were inverse age (best-fitting age effect for MI), age + age2
(best-fitting for CHD and CVD), log age + (log age)2, (log
age)0.5 and log age. The increase in the relative risk of
events from age 40 to 65 years using the best-fitting age
effects are plotted in Figure 1. This figure illustrates that
the differing age effects fitted all gave similar increasing
risks of events.
Figure S1 shows the relative risk increases with age for
each of the five sensitivity analyses. The broad increasing
risk of events with age remained consistent and similar
across the sensitivity analyses, demonstrating the overall
robustness of the fitted age effects. The greatest deviations
seemed to be when we adjusted for calendar year, or time
since cohort entry. In these analyses, the increasing relative
risk with age appeared to be slightly higher.
Comparison with general population risk equations
Figure 2 compares the D:A:D relative risk increase with
age with those from the general population equations. In
D:A:D there was an increasing risk of CHD and CVD per
year older, which was modestly raised compared with
the general population-based equations for CHD and CVD.
For CHD, at age 65 years, an HIV-positive person was at
5.75-fold increased risk (95% CI 4.65, 7.12) compared with
age 40 years, while for the general population these rela-
tive risks were 3.34 (FHS_W), 3.79 (FHS_A) and 4.85
(CUORE). For CVD, at age 65 years the relative risk for an
HIV-positive person compared with age 40 years was 5.84
(95% CI 4.85, 7.02), while in the general population the
relative risks were 4.16 (ASSIGN), 4.42 (FHS_D) and 4.73
(FHS_A). Equally, the risk of MI at age 65 years relative
to age 40 years was 4.00 for HIV-positive individuals in
D:A:D and 4.40 for the general population (FHS_A).
Risk modification
Stopping smoking, reducing cholesterol, or reducing sys-
tolic blood pressure at age 50 years all reduced the risk of
CVD (Fig. 3). If smoking is ceased at age 50 years, the risk
of CVD at age 65 years relative to age 40 years can be
reduced from 5.84 to 3.04. Similarly, reducing cholesterol
by 1 mmol/mL from the age of 50 years reduced the rela-
tive risk at age 65 years to 4.78, and reducing systolic
blood pressure by 10 mmHg reduced the relative risk to
5.20. This modelling of risk modification assumes an
instantaneous change in relative risk; however, in reality
we would expect the change in risk to occur more slowly.
For example, the effect of smoking cessation would prob-
ably occur within 1 to 2 years.
Table 1 Patient characteristics at baseline
Number of participants 24 323
Number of MI/CHD/CVD events 474/683/884
Time at risk (person-years) 139115
Age (years) [median (IQR)] 40.68 (35.21–47.74)
cART exposure (years) [median (IQR)] 1.94 (0.01–3.87)
NRTI exposure (years) [median (IQR)] 2.58 (0.21–5.27)
NNRTI exposure (years) [median (IQR)] 0.00 (0–1.10)
PI exposure (years) [median (IQR)] 0.86 (0–3.13)
CD4 count (cells/μL) [median (IQR)] 440 (288–630)
Systolic blood pressure (mmHg) [median (IQR)] 120 (115–133)
Diastolic blood pressure (mmHg) [median (IQR)] 80 (70–85)
Total cholesterol (mmol/l) [median (IQR)] 4.90 (4.06–5.80)
HDL cholesterol (mmol/l) [median (IQR)] 1.09 (0.88–1.32)
Total:HDL cholesterol ratio [median (IQR)] 4.49 (3.51–5.71)
Triglycerides (mmol/l) [median (IQR)] 1.69 (1.10–2.70)
BMI (kg/m2) [median (IQR)] 23.25 (21.37–25.39)
HIV RNA < 50 copies/mL [n (%)] 11 144 (46.23)
Family history of CVD [n (%)] 2083 (8.56)
Diabetes mellitus [n (%)] 815 (3.35)
Current cigarette smoker [n (%)] 13 134 (55.24)
Ex-smoker [n (%)] 4032 (17.69)
Transmission group [n (%)]
Heterosexual 4996 (20.54)
Homosexual 14 525 (59.72)
Injecting drug user 3529 (14.51)
Other/unknown 1273 (5.23)
Ethnicity [n (%)]
White 14 469 (59.49)
Non-white 1372 (5.65)
Unknown 8482 (34.87)
BMI, body mass index; cART, combination antiretroviral therapy; CHD,
coronary heart disease; CVD, cardiovascular disease; HDL, high-density
lipoprotein; IQR, interquartile range; MI, myocardial infarction; NRTI,
nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
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Discussion
In this study, we modelled in detail the relative increased
risk of MI, CHD and CVD per year older in D:A:D and
compared it with the relative increased risk of these events
per year older obtained using general population CVD risk
equations. In our study, the risk of CVD events increased
consistently with age. We observed only limited evidence
of a greater increased risk with ageing in D:A:D compared
with the corresponding increased risk with ageing based on
general population equations of similar design for most of
the general population equations for CHD and CVD, and we
found no such evidence for MI. Thus, it remains difficult to
conclude with any certainty that the relative risk of ageing
was appreciably raised in D:A:D.
Our study compared the relative risk increase with
ageing, as it is not possible to account for an absolute risk
difference between HIV-positive and HIV-negative popu-
lations. A few studies have attempted to determine the
impact (or contribution) that HIV infection itself has on
increased risk [5,6,20]. Triant et al. [5], in a health care
system-based cohort, found an increased relative risk of
1.75 in acute MI rates among HIV-positive people com-
pared with HIV-negative people after adjustment for tra-
ditional risk factors. This group also found diverging rates
of MI between HIV-positive and HIV-negative people with
increasing age [5]. To understand how our results compare
with the Triant et al. findings, we fitted the D:A:D MI
relative risks to the estimates reported in Triant et al. for
men, using the youngest age group as the reference cat-
egory [5]. We also then applied the relative risk of MI
in HIV-positive men compared with HIV-negative men
reported in Triant et al. to the D:A:D ageing effect to
illustrate how the HIV-negative population also compared.
Our results show quite a good fit for both HIV-positive
and HIV-negative trends (Fig. 4), suggesting that the effect
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Fig. 1 Comparison of the top five best-fitting modelled age effects for coronary heart disease (CHD), cardiovascular disease (CVD) and myocardial
infarction (MI). Age effects: age + (age)2, continuous line; inverse age, dashed line; log(age), long-dashed−short-dashed line; log(age) + [log(age)]2,
long-dashed line; [log(age)]0.5, short-dashed line.
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of HIV infection on the risk of CVD is not unlike that of
other risk factors, such as the effect of smoking, where the
absolute CVD risk increases with age more in smokers than
in nonsmokers.
One modifiable CVD risk factor for HIV-positive patients
is ART. We have previously demonstrated in the D:A:D
study risk equation [11] that the per year additional risk
of CVD, CHD and MI among patients receiving lopinavir
ranged from 8 to 12% per year, with almost a doubling in
risk over 10 years. Current use of abacavir increased the
risk of CVD, CHD and MI by 1.63, 1.73 and 2.03 times,
respectively. We estimated the ageing effect on the risk for
CVD, CHD and MI to be about a 2-fold increased risk per
decade older (see Fig. 1). Hence our results suggest that
reducing exposure to lopinavir by 10 years or stopping
abacavir roughly corresponds to being a decade younger in
terms of CVD risk.
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Fig. 3 Relative risk of cardiovascular disease (CVD) from age 40 years
including stopping smoking, reducing cholesterol (by 1 mmol/L) or
reducing systolic blood pressure (SYS_BP) (by 10 mmHg) at age 50 years.
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Fig. 2 Relative risk of coronary heart disease (CHD), cardiovascular disease (CVD) and myocardial infarction (MI) from age 40 years for D:A:D and
respective general population equations: FHS_A (Framingham Heart Study, Anderson et al. [12]), FHS_W (Framingham Heart Study, Wilson et al. [13]),
FHS_D (Framingham Heart Study, D’Agostino et al. [14]), CUORE and ASSIGN. Risk equations: D:A:D equation in all three panels, continuous line (95%
confidence limits, blue shaded area); FHS_A, long-dashed line (all three endpoints); FHS_W, dashed line (CHD endpoint); FHS_D, short-dashed
line (CVD endpoint); CUORE, very short-dashed line (CHD endpoint); ASSIGN, long-dashed−short-dashed line (CVD endpoint).
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The AGEhIV cohort study reported that the overall
prevalence of age-associated noncommunicable comor-
bidity (AANCC) was significantly greater in HIV-positive
people compared with well-matched HIV-negative people
(75% vs. 62%, respectively) based on self-report. After
adjustment for age, gender and smoking, longer docu-
mented duration of HIV-seropositivity was associated
with a significantly higher risk of an increasing number
of AANCCs [odds ratio (OR) 1.7; 95% CI 1.07–1.27].
A similar burden of AANCC appeared to occur 5 years
earlier in HIV-positive people compared with HIV-
negative people [21]. In a cross-sectional study compar-
ing rates of MI in HIV-positive people and the general
French population, a relative risk of 1.5 was reported
[20], while some others have reported similar relative
rates for various CVD endpoints for HIV-positive people
compared with HIV-negative populations of around 1.6–
1.7 [6,7]. Taken together, these studies suggest that HIV
infection increases the absolute risk of CVD by about
1.2- to 2-fold.
While the literature to date suggests that HIV infection
does appear to increase the risk of CVD, most of these
studies relied on insufficiently matched controls, and were
mostly cross-sectional in nature. It is well known that
HIV-positive people have a greater prevalence of several of
the traditional CVD risk factors, in particular smoking
[22–24]. Until data from appropriately designed cohort
studies are reported, the absolute risk of CVD for an HIV-
positive person relative to an HIV-negative person and the
impact of HIV infection itself will remain uncertain.
It is somewhat encouraging that the risk of CVD does not
appear to rapidly increase with age in HIV-positive people.
First, there are a number of modifiable risk factors, such as
smoking, cholesterol and blood pressure, that, when treated,
can quite markedly reduce an individual’s CVD risk.
Smoking is of particular importance in HIV-positive popu-
lations with prevalence rates consistently between 40% and
70% [22,25–27], and conferring a 2-fold or greater increased
risk of CVD in HIV-positive patients [9,28]. We have also
previously shown in D:A:D a decreasing risk of CVD for
every additional year of having stopped smoking, similar to
that seen the general population [29]. In our current analy-
ses where we illustrated the effect of stopping smoking and
reducing cholesterol and systolic blood pressure, we showed
not only a reduction in the absolute risk of CVD but also a
slowing of the increase in risk with age (Fig. 4). Secondly,
HIV-positive patients receiving ART are seen regularly
as part of their HIV care. This provides opportunities for
counselling, monitoring and intervention regarding modi-
fiable CVD risk factors in a more complete manner than may
be possible in the general population. Treatment guidelines
for CVD interventions have also more recently been devel-
oped for HIV-positive patients.
Limitations
We were not able to perform formal statistical comparisons
of the age effects with the general population, and have
had to rely on more qualitative comparison. We were,
however, able to include CIs on the D:A:D estimates, giving
some idea of variability. Analysing a number of endpoints,
and comparing with the available general population risk
equations, also provided insight into the consistency of
results.
Furthermore, lack of statistical power meant that we
were unable to accurately estimate the relative risk for
women. In D:A:D we have shown that the relative risk of
CVD in women is approximately 0.7 to that of men [11].
This is not inconsistent with general population studies,
where similar risks have been shown [14,16]. In the
Framingham study [14], the age effect in women was
approximately half that in men, although it was modelled
separately to that in men. However, in the few studies to
date that have compared HIV-positive women with HIV-
negative women, not only were HIV-positive women at
higher risk for CVD compared with HIV-negative women,
but the relative risk was greater than that observed for
HIV-positive men compared with HIV-negative men [5,20].
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Fig. 4 Application of D:A:D relative risk of myocardial infarction (MI)
to Triant et al. estimates of MI in HIV-positive relative to HIV-negative
men. Estimates with 95% confidence bounds are MI rates reported in
Triant et al. [5] for HIV-positive (diamond shaped point estimates) and
HIV-negative men. The D:A:D MI relative risks were fitted to the esti-
mates reported in Triant et al. for men, using the youngest age group as
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Triant et al. was applied to the D:A:D ageing effect (the lower fitted line;
HIV negative RR).
Increased risk of CVD with age in HIV-positive men 601
© 2014 British HIV Association HIV Medicine (2014), 15, 595–603
Finally, our models extrapolate over a 25-year period
(age 40 to 65 years) and beyond based on a median
follow-up of 6 years. Hence our models essentially assume
that the effect of ageing is independent of the duration of
infection and treatment. We have previously shown a 26%
increased risk of MI per year of exposure for up to 6 years
[9]. Given that effective combination therapy for HIV has
only been available for some 15 years, this is an unverifi-
able assumption. A small proportion (5%) of patients in
D:A:D have a total duration of infection of over 20 years at
the end of follow-up.
In conclusion, we found only limited evidence of the risk
of CVD with age in D:A:D increasing more rapidly than in
the general population. HIV-positive patients in clinical
care are routinely assessed, which may allow clinicians to
intervene early. Interventions can reduce these CVD risks,
and guidelines specific for the reduction of CVD risk have
been developed for HIV-positive patients.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Fig. S1 Sensitivity analyses for coronary heart disease
(CHD), cardiovascular disease (CVD) and myocardial
infarction (MI) endpoints. Sensitivity analyses: dark blue
continuous line, final age effect in all three panels
(age + age2 for CHD and CVD and inverse age for MI). The
remaining lines are the final age effects adjusted for cal-
endar year (green long-dashed line), participating cohort
(red dashed line), time since entry into D:A:D (orange short
dashed line), age < 65 years (black long-dashed−short-
dashed line), and men regardless of missing CVD risk
factors (purple short-dashed−dotted line).
Table S1 Age effects for myocardial infarction (MI), coro-
nary heart disease (CHD) and cardiovascular disease (CVD)
and respective Akaike information criterion (AIC).
Appendix S1 D:A:D participating cohorts.
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